XFOR
X4 Pharmaceuticals, Inc
NASDAQ · Healthcare · Biotechnology · US
$3.58
+2.29%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.19
- Revenue estimate
- $2.3M
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.13
- EPS estimate
- -$0.18
- Revenue actual
- $8.8M
- Revenue estimate
- $2.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +19.5%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $11
- PT range
- $11 – $11
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | -$0.18 | -$0.13 | Beat 26.14% | $8.8M |
| May 6, 2026 | -$0.20 | -$0.16 | Beat 20.00% | $2.5M |
| Mar 17, 2026 | -$0.27 | -$0.22 | Beat 19.27% | $2.6M |
| Nov 5, 2025 | -$0.79 | -$0.69 | Beat 12.66% | $1.8M |
| Aug 8, 2025 | -$4.53 | -$3.47 | Beat 23.40% | $2.0M |
| May 1, 2025 | -$4.13 | $0.04 | Beat 100.97% | $28.8M |
| Mar 25, 2025 | -$5.11 | -$6.01 | Miss -17.61% | $1.4M |
| Nov 13, 2024 | -$0.17 | -$0.18 | Miss -5.88% | $560.0K |
| Aug 8, 2024 | -$0.05 | -$0.07 | Miss -40.00% | $563.0K |
| Mar 21, 2024 | -$0.15 | -$0.10 | Beat 33.33% | $3.1M |
| Nov 9, 2023 | -$0.15 | -$0.01 | Beat 93.33% | — |
| Aug 10, 2023 | -$0.17 | -$0.33 | Miss -94.12% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026